Penumbra, Inc. (NYSE:PEN) EVP Johanna Roberts Sells 600 Shares

Penumbra, Inc. (NYSE:PEN) EVP Johanna Roberts sold 600 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $244.49, for a total value of $146,694.00. Following the sale, the executive vice president now owns 63,444 shares of the company’s stock, valued at $15,511,423.56. The trade was a 0.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Johanna Roberts also recently made the following trade(s):

• On Monday, November 18th, Johanna Roberts sold 600 shares of Penumbra stock. The shares were sold at an average price of $239.74, for a total transaction of $143,844.00.
• On Tuesday, October 1st, Johanna Roberts sold 600 shares of Penumbra stock. The shares were sold at an average price of $190.76, for a total value of $114,456.00.

Penumbra Trading Up 0.2 %

Shares of PEN stock traded up $0.40 on Tuesday, hitting $245.24. The stock had a trading volume of 279,206 shares, compared to its average volume of 378,372. The company has a fifty day moving average price of $218.84 and a two-hundred day moving average price of $199.03. The company has a current ratio of 5.82, a quick ratio of 3.25 and a debt-to-equity ratio of 0.02. The firm has a market cap of $9.41 billion, a P/E ratio of 285.16, a PEG ratio of 2.46 and a beta of 0.51. Penumbra, Inc. has a twelve month low of $148.00 and a twelve month high of $277.34.

Penumbra (NYSE:PEN) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $0.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.16. Penumbra had a return on equity of 8.99% and a net margin of 2.97%. The business had revenue of $301.04 million during the quarter, compared to analyst estimates of $297.36 million. During the same period in the previous year, the firm earned $0.67 EPS. Penumbra’s quarterly revenue was up 11.1% compared to the same quarter last year. As a group, analysts forecast that Penumbra, Inc. will post 2.81 earnings per share for the current fiscal year.

Penumbra announced that its Board of Directors has initiated a stock repurchase plan on Tuesday, August 13th that allows the company to repurchase $200.00 million in outstanding shares. This repurchase authorization allows the company to repurchase up to 2.6% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s management believes its shares are undervalued.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Tidal Investments LLC lifted its position in shares of Penumbra by 276.9% in the first quarter. Tidal Investments LLC now owns 4,971 shares of the company’s stock valued at $1,109,000 after buying an additional 3,652 shares during the last quarter. Renaissance Technologies LLC acquired a new position in Penumbra in the second quarter valued at about $17,943,000. Thrivent Financial for Lutherans grew its stake in Penumbra by 3,832.3% during the third quarter. Thrivent Financial for Lutherans now owns 368,298 shares of the company’s stock worth $71,564,000 after buying an additional 358,932 shares in the last quarter. Vontobel Holding Ltd. bought a new position in Penumbra in the third quarter valued at about $1,092,000. Finally, AlphaCentric Advisors LLC acquired a new stake in shares of Penumbra during the 3rd quarter valued at $777,000. 88.88% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Penumbra in a research report on Thursday, October 31st. Piper Sandler raised their price objective on shares of Penumbra from $235.00 to $250.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 20th. Citigroup raised their price target on shares of Penumbra from $178.00 to $200.00 and gave the stock a “neutral” rating in a research report on Thursday, August 22nd. Canaccord Genuity Group lifted their target price on Penumbra from $176.00 to $235.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. Finally, Royal Bank of Canada increased their price target on shares of Penumbra from $205.00 to $222.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. Five investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $230.92.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.